Search results
Showing 7261 to 7275 of 7707 results
GID-MT563 NPi-200 for pupillary light reflex in critical care patients
Discontinued [GID-MT563]
In development [GID-TA11033] Expected publication date: TBC
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)
Discontinued [GID-MT517]
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]
In development [GID-TA11265] Expected publication date: TBC
In development [GID-TA11443] Expected publication date: TBC
In development [GID-TA11252] Expected publication date: TBC
This guideline has been updated and replaced by NICE guideline NG240.
In development [GID-TA10783] Expected publication date: TBC
In development [GID-TA11274] Expected publication date: TBC
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]
In development [GID-TA11109] Expected publication date: TBC
This guidance has been updated and replaced by NICE technology appraisal guidance 953.
This guidance has been updated and replaced by NICE technology appraisal guidance 684.
NICE has withdrawn this guidance. Takeda will stop marketing mobocertinib (Exkivity) and its marketing authorisation has been withdrawn. Healthcare professionals should discuss alternative treatment options with people currently having mobocertinib.
Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)
This evidence summary has been updated and replaced by NICE guideline 115.